Kezar Life Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KZR research report →
Companywww.kezarlifesciences.com
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.
- CEO
- Christopher J. Kirk
- IPO
- 2018
- Employees
- 55
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $53.86M
- P/E
- -1.18
- P/S
- 0.00
- P/B
- 0.82
- EV/EBITDA
- 0.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.35%
- ROIC
- -63.08%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-56,033,000 · 33.08%
- EPS
- $-7.66 · -566.09%
- Op Income
- $-52,270,000
- FCF YoY
- 30.25%
Performance & Tape
- 52W High
- $7.55
- 52W Low
- $3.53
- 50D MA
- $7.13
- 200D MA
- $5.81
- Beta
- 0.41
- Avg Volume
- 87.92K
Get TickerSpark's AI analysis on KZR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Wallace Courtney | sell | 3,500 |
| May 11, 26 | Wallace Courtney | sell | 5,000 |
| May 11, 26 | Wallace Courtney | sell | 5,000 |
| May 11, 26 | Wallace Courtney | sell | 2,600 |
| May 11, 26 | Schiller Mark C. | other | 2,739 |
| May 11, 26 | Schiller Mark C. | sell | 25,000 |
| May 11, 26 | Schiller Mark C. | sell | 24,500 |
| May 11, 26 | Schiller Mark C. | sell | 12,000 |
| May 11, 26 | Schiller Mark C. | sell | 16,499 |
| May 11, 26 | Klearman Micki | sell | 3,500 |
Our KZR Coverage
We haven't published any research on KZR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KZR Report →